Search
Reduction in Risk of Recurrence of
Overt Hepatic Encephalopathy (HE)
View highlights of the Bass NM, et al. article published in New England Journal of Medicine on the use of rifaximin for the reduction in risk of overt HE recurrence
Evaluation of Treatment Effect on
Symptoms of Irritable Bowel Syndrome With Diarrhea (IBS-D)
View highlights from the Pimentel M, et al. article published in New England Journal of Medicine on two-week course of rifaximin for patients with IBS-D
Analysis of Repeat Treatment Effect for
Irritable Bowel Syndrome With Diarrhea
(IBS-D) Symptom Recurrence
View highlights from the Lembo A, et al. article published in Gastroenterology on two-week repeat rifaximin course in initial IBS-D symptom responders
Evaluation of Treatment Effect on Symptom of Bloating in Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Click to watch a presentation at the United European Gastroenterology Week by Dr Brian E. Lacy
of a pooled analysis of three phase 3, randomized, placebo-controlled trials on the efficacy of
rifaximin on bloating in patients with diarrhea-predominant irritable bowel syndrome
Therapeutic Areas
Learn more about irritable bowel syndrome (IBS) with diarrhea (IBS-D), IBS with constipation (IBS-C), and chronic idiopathic constipation.
Learn more about the signs, symptoms, and potential underlying mechanisms of overt HE, a complication of cirrhosis.
Search
*Required field.
Select a product*
Select a therapeutic area*
Enter keyword(s)
Additional Resources
Access posters and abstracts shared during scientific congresses.
View product- and therapeutic area–related publications appearing in peer-reviewed journals.
Request a meeting with a Medical Science Liaison (MSL), a field-based expert in our medicines and clinical research.
Request support for independent medical education efforts or investigator-initiated clinical research.
IBS-D
Search
*Required field.
Select a product*
Select a therapeutic area*
Enter keyword(s)